Two Sigma Advisers
LGND icon

Two Sigma Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Two Sigma Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,300
Closed -$314K – 2578
2024
Q1 		$314K Sell
4,300
-1,100
-20% -$81.1K ﹤0.01% 2058
2023
Q4 		$386K Sell
5,400
-1,200
-18% -$70.8K ﹤0.01% 2021
2023
Q3 		$395K Sell
6,600
-1,000
-13% -$65.8K ﹤0.01% 1876
2023
Q2 		$548K Sell
7,600
-800
-10% -$60K ﹤0.01% 1777
2023
Q1 		$618K Sell
8,400
-3,100
-27% -$220K ﹤0.01% 1856
2022
Q4 		$768K Buy
11,500
+7,332
+176% +$477K ﹤0.01% 1697
2022
Q3 		$224K Sell
4,168
-160
-4% -$9.41K ﹤0.01% 2161
2022
Q2 		$241K Buy
4,328
+801
+23% +$45.5K ﹤0.01% 2204
2022
Q1 		$247K Buy
3,527
+481
+16% +$34.9K ﹤0.01% 2312
2021
Q4 		$293K Buy
+3,046
New +$281K ﹤0.01% 2149
2021
Q2 		– Sell
-36,664
Closed -$3.49M – 2577
2021
Q1 		$3.49M Sell
36,664
-56,586
-61% -$5.35M 0.01% 1009
2020
Q4 		$5.79M Sell
93,250
-182,421
-66% -$10.4M 0.02% 764
2020
Q3 		$16.4M Sell
275,671
-37,190
-12% -$2.54M 0.05% 370
2020
Q2 		$21.8M Buy
312,861
+5,290
+2% +$335K 0.06% 304
2020
Q1 		$14M Sell
307,571
-94,897
-24% -$5.38M 0.05% 380
2019
Q4 		$26.2M Sell
402,468
-21,962
-5% -$1.47M 0.06% 320
2019
Q3 		$26.4M Sell
424,430
-86,722
-17% -$5.44M 0.06% 320
2019
Q2 		$36.4M Sell
511,152
-15,389
-3% -$1.13M 0.09% 266
2019
Q1 		$41.3M Buy
526,541
+248,145
+89% +$18.8M 0.1% 242
2018
Q4 		$23.6M Buy
278,396
+33,156
+14% +$3.53M 0.06% 343
2018
Q3 		$42M Sell
245,240
-55,464
-18% -$8.36M 0.1% 234
2018
Q2 		$38.9M Buy
300,704
+57,067
+23% +$6.37M 0.1% 242
2018
Q1 		$25.1M Buy
243,637
+221,695
+1,010% +$21.9M 0.07% 352
2017
Q4 		$1.87M Buy
21,942
+14,427
+192% +$1.25M 0.01% 1278
2017
Q3 		$638K Buy
7,515
+4,809
+178% +$381K ﹤0.01% 1662
2017
Q2 		$205K Buy
+2,706
New +$189K ﹤0.01% 2112
2016
Q1 		– Sell
-3,514
Closed -$238K – 2086
2015
Q4 		$238K Sell
3,514
-1,122
-24% -$69.3K ﹤0.01% 1595
2015
Q3 		$248K Buy
4,636
+160
+4% +$9.71K ﹤0.01% 1569
2015
Q2 		$282K Sell
4,476
-41,197
-90% -$2.25M ﹤0.01% 1638
2015
Q1 		$2.2M Buy
45,673
+1,924
+4% +$73.7K 0.02% 728
2014
Q4 		$1.45M Buy
43,749
+8,977
+26% +$292K 0.01% 977
2014
Q3 		$1.02M Buy
34,772
+8,015
+30% +$266K 0.01% 1120
2014
Q2 		$1.04M Buy
26,757
+17,793
+198% +$722K 0.01% 1168
2014
Q1 		$377K Buy
+8,964
New +$374K ﹤0.01% 1725
2013
Q3 		– Sell
-15,055
Closed -$352K – 2264
2013
Q2 		$352K Buy
+15,055
New +$271K 0.01% 1601

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Two Sigma Advisers's LGND Position: Q2 2024 in Review

Two Sigma Advisers sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 4,300 shares — an estimated $314K sold.

Two Sigma Advisers first reported a position in LGND in Q2 2013 and held it in 35 quarters. The position peaked at $42M in Q3 2018. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Two Sigma Advisers reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 4,300 Ligand Pharmaceuticals shares in Q2 2024, an estimated $314K.
  • Two Sigma Advisers first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 35 quarters.
  • Two Sigma Advisers's Ligand Pharmaceuticals position peaked at $42M in Q3 2018.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Two Sigma Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.